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man correlations, and a ROC analysis was used to determine the individual contribu-





Results: The individual markers measured on admission contributing most strongly 
to	 prediction	 of	COVID-19	 severity	 as	 assessed	 at	 discharge	were	 LDH,	CRP	 and	
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1  | INTRODUC TION
The	 clinical	 spectrum	 of	 SARS-CoV-2	 infection	 appears	 to	 be	
wide, encompassing asymptomatic infection, mild upper respi-
ratory tract illness with cough, fever and fatigue to more severe 
viral pneumonia with a risk of consequent respiratory failure and 
death. Risk factors associated with symptomatic disease requiring 
hospitalization	are	uncertain	and	factors	that	influence	the	risk	of	
developing	 severe	disease	 remain	 incompletely	understood.	Age	
has been consistently associated with increased mortality1; type 
2 diabetes and hypertension, two most prevalent comorbidities 
in	 hospitalized	 patients	 have	 been	 also	 associated	 with	 severe	
manifestations.2–4
Recent data coming from the US and Western Europe show 
that being overweight or obese is a significant risk factor asso-
ciated	 with	 hospitalization,5 requirement to mechanical venti-
lation6,7	 and	 in-hospital	mortality	 from	COVID-19.1	A	number	of	
mechanisms	may	 underlie	 association	 of	 body	mass	 index	 (BMI)	
and pneumonia including increased airway resistance and reduced 
respiratory muscle strength, lung volumes, and gas exchange.8 
However,	it	has	emerged	that	patients	with	high	BMI	are	at	greater	
risk	of	death	from	COVID-19	than	patients	with	asthma.1 This sug-
gests	 that	 the	mechanisms	by	which	SARS-Cov2	develops	 into	a	
severe	 form	 of	 COVID-19	 may	 be	 directly	 related	 to	 metabolic	
pathways that are specifically dysregulated in obese or overweight 
individuals. Obesity is also a key risk factor for type 2 diabetes, 
hypertension and cardiovascular disease all of which have been 
associated	 with	 COVID-19.	 Furthermore,	 metabolic	 impairment	
characterized	 by	 insulin	 resistance,	 hyperglycaemia	 and	 dyslipi-
daemia	may	remain	unrecognized	in	substantial	proportion	of	the	
population.9 Evaluating of these parameters is important to risk 
stratify	patients	with	COVID-19.10
The objective of this study was to identify risk factors for symp-
tomatic	COVID-19	and	the	development	of	 its	severe/critical	form	
using	a	multicentre	retrospective	cohort	of	610	patients	with	COVID-
19 from Zhejiang province, China. In particular, we have investigated 
to	what	 extent	 the	 effects	 of	 high	BMI	 (BMI	of	 ≥	 23	 kg/m2).11 of 
COVID-19	severity	in	the	current	cohort	are	mediated	by	systemic	
inflammation and how much by LDH, glycemia or hypertension.
2  | PATIENTS AND METHODS
The study protocol conformed to the ethical guidelines of the 1975 
Declaration of Helsinki. The local ethics committees of all hospitals 
approved	 the	 retrospective	 study	 of	 cohorts	 COVID-19.	 The	 re-
quirement for written consent was waived due to the retrospective 
and anonymous nature of this study.
2.1 | Cohort of cases





Pneumonia	 (fifth	 edition)	 formulated	 by	 the	 National	 Health	




included in the study. The clinical data of all patients were collected 
F I G U R E  1   Flow chart of recruitment path for research study 
participants
610 consecutive Covid-19 patients 












18 were not permanent 
resident of Zhejiang Province;








is mediated by systemic inflammation.
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from	the	electronic	medical	records.	All	patients	were	administered	
with antiviral and supportive treatments, and prevention of compli-
cations based on their clinical conditions.
2.2 | Clinical categories
The severity of the disease was classified according to the 
Guidelines	 for	 the	Diagnosis	and	Treatment	of	New	Coronavirus	
Pneumonia	 (fifth	edition)12	 and	categorized	 into	4	groups	as	de-
scribed previously.13 In brief, patients were classified into the fol-
lowing groups:
1. Mild: patients with mild clinical symptoms and no pulmonary 
changes on CT imaging
2. Common: patients with symptoms of fever and signs of respira-
tory infection, and having pneumonia changes on CT imaging
3. Severe: patients presenting with any one item of the following: 
a)	respiratory	distress,	 respiratory	rate	≥	30/min,	b)	oxygen	sat-
uration	of	 finger	≤	93%	 in	 resting	condition,	and	c)	arterial	par-




ICU admission requirement due to multiple organ failure
2.3 | Analyses of severity
Individual demographic and clinical features were tested for asso-
ciation	with	 the	4-point	 scale	of	 severity	 described	 above	using	 a	
Spearman's correlation. Those variables that were significantly asso-





Clinical	 laboratory	 test	 results,	 including	 SARS-CoV-2	 RNA	 de-
tection results, biochemical indices, blood routine results, were 
collected from routine clinical practice across all 14 centres. 
SARS-CoV-2	RNA	was	detected	using	real-time	quantitative	PCR	
(qPCR)	 on	 nucleic	 acid	 extracted	 from	 upper	 respiratory	 swab	
samples. Upper respiratory swab samples were collected on all 
suspected	 cases	 of	 SARS-CoV-2	 infection	 on	 admission	 and	 im-
mediately placed into sterile tubes with viral transport medium. 
All	 biochemical	 and	 haematology	 parameters	were	 obtained	 via	
standard automated laboratory methods and using commercially 
available kits following to the manufacturer's protocols. Clinical 
and laboratory data are those collected and recorded at the time 
of admission.
2.5 | Statistical methods
Categorical variables were expressed as frequency and percent-
ages. Continuous variables were expressed as mean and standard 
deviations. Logistic regressions were carried out either unadjusted 
or adjusting for covariates as indicated in the table legends. p < .05 
was considered statistically significant. To formally assess the con-
tribution of CRP, LDH, glycemia and hypertension to the association 
between	BMI	and	disease	severity,	we	conducted	mediation	analysis	
using the ‘mediation’ package in R version 3.6.1 where we consid-
ered the various clinical traits as mediator for the causal effect of 
BMI	on	severity.
Analyses	were	carried	out	using	R	version	3.6.1.	p	< .05 was con-
sidered statistically significant.
3  | RESULTS
The selection of the study population was carried based on a previ-
ously published protocol.13
We proceeded to investigate the biochemical and clinical factors 
that correlate with the disease severity. The demographic, clinical 
presentation features and biochemical markers in each of the four 
severity	categories	are	shown	in	Table	1.	We	found	that	BMI	greater	
than 23 kg/m2 was strongly associated with a more severe form of 
the	disease,	but	BMI	below	23	kg/m2 was not. We also found sig-
nificant associations with male sex and older age. In terms of the 
biochemical measures, we found glucose and LDH having the most 
dramatic effect on severity compared to others. The presence of 
hypertension was significantly associated with severity, but type 2 
diabetes was not.
We further ranked the biochemical markers correlated with 
severity and put them side by side with some of the demographic 
characteristics in terms of how much they can explain severity on 
a	 ROC	 analysis	 including	 each	 variable	 independently	 (Figure	 2).	
We found that levels of LDH, CRP and glucose on admission were 
each	individually	able	to	predict	75%	or	more	of	COVID-19	severity.	
Furthermore, we found that LDH was a greater predictor of severity 
(beta	 0.426;	 0.320–1.870	 95%	CI;	 p	<	 .001)	 compared	 to	 glucose	
(beta	 0.264;	 0.188–1.495	 95%	CI;	 p	<	 .001)	 and	CRP	 alone	 0.20;	
0.106–0.238	95%	CI;	p	<	.001).
Given	the	strong	links	between	CRP,	glucose	and	LDH	with	BMI,	
we decided to investigate whether the relationship observed in 
other	cohorts	between	BMI	and	COVID-19	severity	might	actually	
be mediated by these factors.
We	next	hypothesized	that	part	of	the	association	of	BMI	with	
severity	 is	mediated	 by	 high	 glucose	 levels	 (hyperglycaemia),	 CRP	
and LDH. In order to test the mediatory effect of these variables, 
we carried out a formal mediation analysis where LDH, hypergly-
caemia	(glucose	>	8mmol/l)	and	CRP	were	fitted	as	mediators	of	the	
effect	of	BMI	on	severity.	We	observed	a	partial	mediation	effect	
for glucose and CRP where both the average causal mediation effect 





we also explored the mediatory effect of hypertension, given its 
strong links to metabolic syndrome and found that it mediated 66% 
(p	<	.001)	of	the	effect	of	BMI	on	severity	as	shown	in	Table	2.	We	
also	carried	a	regression	analysis	of	severity	with	glucose	and	BMI	
and	 found	 significant	 associations	 for	 glucose	 (beta	=	 0.25,	 0.89–
1.53 95% CI, p=<0.001)	and	for	BMI	(beta	= 0.14, 0.33–1.25 95%CI, 
p =	 .001).	 Furthermore,	 a	 regression	 of	 glucose	 on	 BMI	was	 also	
found	to	be	significant	(beta	= 0.14, 0.77–0.27 95% CI, p =	.001).
TA B L E  1  Association	between	demographics,	biochemical	measures,	comorbidities	and	severity.	odds	ratios	were	derived	by	logistic	
regression	severe	(severe	+	critical)	vs	not	severe	(mild	+	common).	p-values	adjusted	for	age,	sex	and	BMI,	except	those	for	age,	sex	and	
BMI
Severity category 1 (mild) 2 (common) 3 (severe) 4 (critical)
adj OR severe 
vs not 95% CI p-value
Demographic & clinical parameters
n 32 450 95 33
Sex M 19	(59.3%) 207	(46.0%) 61	(64.2%) 25	(75.7%) 2.3 1.5 3.5 <.0001
Age	years	mean	(SD) 40.8(12.4) 47.2(13.5) 53.7	(13.4) 62.4	(14.7) 1.0 1.0 1.0 <.0001
BMI	kg/m2	mean	(SD) 23.3	(3.5) 23.6	(3.3) 25.5	(3.6) 25.0	(3.5) 1.1 1.1 1.2 <.0001
BMI	< 23 kg/m2	(SD) 20.2(1.2) 21.8	(1.5) 20.4	(2.0) 21.3	(1.5) 0.1 0.7 1.3 .955
BMI	> 23 kg/m2	(SD) 25.7(2.6) 25.8(2.5) 26.6	(2.8) 26.4	(2.9) 1.1 1.0 1.2 .001
Smoker	(%) 14	(43.7%) 61	(13.7%) 26	(27.3%) 14	(42.4%) 0.7 0.5 0.9 .076
Cough	(Respiratory	
Symptoms)	(%)
18	(56.2%) 27	(6%) 75	(78.9%) 30	(91%) 0.9 0.6 0.1 .001
Digestive	Symptoms	(%) 7	(21.8%) 52	(11.5%) 17	(17.9%) 4	(12.1%) 0.8 0.6 0.9 .089
Fever	(%) 23	(71.8%) 366	(81.5%) 84	(88.4%) 28	(84.8%) 0.8 0.6 0.1 .573
Peak	Temperature	(SD) 37.5	(0.6) 37.8	(0.7) 38.0	(0.8) 38.2	(0.9) 1.1 1.0 1.1 .006
Biochemical	measures
Glucose	mmol/l	(SD) 6.0	(1.8) 6.2	(2.1) 6.8	(2.8) 9.0	(3.9) 1.3 1.1 1.4 <.0001
CRP	mg/L	(SD) 4.3	(12.6) 15.8(20.0) 22.3	(24.7) 48.8	(34.2) 1.0 1.0 1.0 <.0001
Lymphocyte	(109/L)	(SD) 1.4	(0.6) 1.2(0.5) 1.1	(0.5) 0.7	(0.4) 0.1 0.08 0.2 <.0001
Monocyte	(109/L)	(SD) 0.5	(0.3) 0.4	(0.2) 0.4	(0.2) 0.4	(0.3) 0.7 0.3 1.6 .519
Neutrophil	(109/L)	(SD) 3.6	(1.5) 3.2	(1.5) 4.9	(5.5) 6.5	(3.4) 1.2 1.2 1.4 <.0001
WBC	(109/L)	(SD) 5.6	(2.0) 5.0	(2.1) 6.2	(5.2) 7.0	(3.3) 1.2 1.1 1.3 <.0001
PLT	(109/L)	(SD) 208.2	(54.2) 198.2	(70.7) 191.4	(63.9) 172.8	(84.5) 0.9 0.9 1.00 .079
HBG*	(g/L)	(SD) 142.3	(11.8) 135.0	(15.4) 136.0	(17.8) 131.8	(19.5) 0.9 0.9 1.01 .724
AST	(iu/L)	(SD) 21.6	(10.2) 26.9	(16.1) 36.8	(21.4) 47.7	(33.7) 1.03 1.02 1.04 <.0001
ALT	(iu/L)	(SD) 27.6(23.3) 27.5	(24.5) 38.6	(33.5) 39.5	(36.6) 1.01 1.0 1.02 .0001
ALB	(g/dl)	(SD) 42.0	(4.2) 41.4	(5.3) 36.1	(4.8) 31.1	(3.7) 0.7 0.6 0.8 <.0001
TC	(mmol/L)	(SD) 4.6	(0.9) 3.9	(0.8) 3.9	(0.8) 3.8	(1.3) 0.9 0.6 1.2 .600
TG	(mmol/L)	(SD) 2.5	(3.1) 1.4(0.7) 1.3	(0.4) 1.3	(0.5) 0.8 0.5 1.2 .481
HDL	(mmol/L)	(SD) 1.0(0.2) 1.1	(0.3) 1.0	(0.2) 1.0	(0.3) 0.3 0.1 0.8 .026
LDL	(mmol/L)	(SD) 2.7	(0.7) 2.2	(0.7) 2.1	(0.6) 2.0	(1.0) 0.7 0.5 1.1 .177
Potassium	(mmol/L)	(SD) 3.8	(0.3) 3.9	(2.4) 3.8(0.5) 3.6	(0.4) 0.7 0.4 1.0 .242
Sodium	(mmol/L)	(SD) 138.9	(2.1) 138.3	(2.8) 136.9	(3.2) 135.5	(7.5) 0.8 0.7 0.9 <.0001
Creatinine	kinase	(iu/L)	
(SD)
69.9	(10.5) 67.6	(18.7) 83.7	(52.3) 95.9	(230.) 1.01 1.0 0.02 .014
LDH	(iu/L)	(SD) 164.4	(41.2) 216.5	(72.7) 329.9	(146) 382.2	(166.5) 1.01 1.01 1.02 <.0001
Comorbidities
Type 2 Diabetes 2	(6.2%) 37	(8.2%) 16	(16.8%) 5	(15.1%) 1.2 0.6 2.2 .565
Hypertension 3	(9.3%) 77	(17.1%) 38	(40.0%) 19	(57.5%) 2.3 1.4 3.7 .0004
*HBG	1	g/L	=	0.1	g/dl.	Bold	values	represent	statistical	significance	
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Finally, although diabetes was not a strong risk factor for sever-
ity, it could be that the high levels of glucose seen to be predictive 
of severity may be only seen in diabetic patients. Therefore, we 
further investigated its effect in patients with and without type 2 
diabetes	 and	 in	 the	overweight/obese	 (BMI	> 23 kg/m2)	 and	nor-
mal	weight	(BMI	< 23 kg/m2)	categories.	We	found	that	glucose	was	
F I G U R E  2   (A)	ROC	AUC	(95%	CI)	and	(B)	Spearman	correlations	for	biochemical	and	demographic	characteristics	ranked	in	order	of	
predicting	COVID-19	severity































































TA B L E  2   Summary statistics of mediation analysis for the various clinical traits
Clinical trait Effect ACME 95% CI p ADE 95% CI p %
Hyperglycaemia Partial 0.2105 0.085–0.26 <.0001 0.0484 0.02–0.07 <0001 79%
CRP Partial 0.0412 0.011–0.17 <.05 0.1047 0.06–0.15 <.001 44%
LDH Full 0.151 0.09–0.21 <.0001 0.042 −0.03 .13 78%
Hypertension Partial 0.1863 0.083–0.23 <.0001 0.0632 0.03–0.10 <.001 66%
Hyperglycaemia + Hypertension Partial 0.3954 0.22–0.57 <.0001 0.0947 0.06–0.14 <.05 86%
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significantly associated with severity in patients with and without 
type	2	diabetes	(Figure	3).	Similarly,	the	association	of	glucose	with	
severity was significant in the overweight/obese category compared 
to the normal weight category. Furthermore, we found that CRP, a 
common marker of systemic inflammation, was significantly associ-
ated with severity in the presence or absence of type 2 diabetes and 
amongst	normal	and	overweight	categories	as	shown	in	Figure	3.	A	
similar pattern was seen with regards to LDH levels.
4  | DISCUSSION
Using a multicentre cohort of 610 patients from Zhejiang province, 





increased risk of admission to acute and critical care settings5–7 as 
well	as	 in-hospital	mortality1 in a cohort of patients from a hospi-
tal	in	New	York	and	UK.	In	the	current	cohort	(n	=	610),	mean	(SD)	
BMI	is	distinctly	lower	at	23.98	(3.47)	kg/m2 and ranged from 23.35 
(3.50)	kg/m2in	those	who	had	mild	form	to	25.02	(3.50)	kg/m2 in the 
group	who	developed	critical	form	of	COVID-19.	This	indicates	that	
the	relationship	of	rising	BMI	in	this	cohort	is	unlikely	to	be	due	to	
reduced cardiorespiratory reserve associated with obesity. It is im-
portant	 to	 note	 that	Asians	 have	 a	 higher	 percentage	 of	 body	 fat	
than	white	people	of	the	same	age,	sex	and	BMI,	hence,	are	deemed	
to	 be	 at	 increased	 risk	 of	 its	 metabolic	 consequences	 at	 a	 BMI	
of	≥	23	kg/m2.11	When	we	grouped	people	using	a	BMI	cut-off	of	
23 kg/m2,	those	with	a	BMI	≥	23	kg/m2;	mean	(SD)	had	a	higher	risk	









in the general population.14–16	Obesity-induced	meta-inflammation	
is associated with systemic increases in circulating inflammatory cy-
tokines and acute phase proteins such as CRP and recruitment of 
leucocytes to inflamed tissues.17 Obesity has also been shown to 
impair	immune	response	to	influenza	virus.18 When we investigated 
the	proportion	of	the	effect	of	BMI	mediated	by	these	two	factors,	
we	found	that	a	higher	proportion	of	the	effect	of	BMI	on	COVID-19	





tes did not affect the relationship between obesity and severity.19 
However, in our study population, half of the patients were 50 or 
older	with	a	median	BMI	of	23.9	and	only	4	 individuals	 in	our	pa-
tient	cohort	had	a	BMI	> 35. It is therefore possible that in younger 
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morbidly obese individuals, the effect of morbid obesity may not be 
mediated by hypertension or diabetes. It is also possible that these 
effects may be related to ethnicity. Increased blood glucose levels at 
a cellular level can result in mitochondrial injury and endothelial dys-
function by generating reactive oxygen species and inhibiting nitric 
oxide production, respectively.20 Hence, glucose in conjunction with 
hypertension	mediates	the	effect	of	BMI	on	COVID-19	severity.
Serum LDH and glucose levels at the time of hospital admis-
sion	 are	 associated	with	 severe/	 critical	 form	of	COVID-19	 in	 our	
cohort	and	mediate	 the	majority	of	 the	effect	of	BMI	on	severity;	




of	166	COVID-19	patients	 from	a	 single	 centre	has	 shown	 fasting	
plasma glucose to be associated with severe form and longer hospi-
tal stay for those with and without diabetes.21	Acute	hyperglycaemia	
can in turn significantly alter innate immune responses to infection, 
and this potentially explains some of the poor outcomes in hospi-
talized	patients	who	develop	hyperglycaemia	as	a	consequence	of	
bacterial and viral infections22 The role of LDH is likely to fit within 
the	same	pathway,	as	increased	levels	of	LDH-A	are	seen	in	immuno-
logical Warburg effects when immune cells carry out glycolysis even 
in	 the	 presence	 of	 oxygen,	 resulting	 in	 a	 strong	 pro-inflammatory	
phenotype.23
Risk stratification of patients at the time of diagnosis would as-
sist planning of interventions for patients at risk of developing se-
vere disease. Important role of baseline glucose levels in determining 
the	development	of	severe	COVID-19	 indicates	 the	potential	ben-
efits	 of	 prioritizing	 glycaemic	 control	 at	 the	 time	of	 diagnosis	 and	
during	 hospitalization.24 Our results have important public health 
implications as they suggest that promoting interventions targeting 
glycaemia25	 may	 prevent	 some	 of	 the	worst	 COVID-19	 outcomes	
seen among overweight and obese individuals,26,27 in particular 
those with prediabetes28 and ethnic minority communities29 where 
metabolic	consequences	of	BMI	are	distinctly	higher.
Limitations of our study include the retrospective nature of the 
COVID-19	cohort,	which	 inevitably	 lead	 to	possible	 variations	be-
tween	hospitals	involved	and	under-recording	of	some	of	the	symp-
toms. However, we have included consecutive cases from each of 
the	 secondary	 care	 hospitals	 to	 reflect	 the	 full	 range	 of	 case-mix	
seen in routine clinical practice. Case definition and assessment of 
severity	 of	 COVID-19	 were	 adherent	 to	 national	 guidelines	 con-
sistently across all the centres involved in this study.11	 Although	
128	of	610	patients	 included	developed	 severe	or	 critical	 form	of	
the disease, mortality rate of < 1% means that we are unable to 
model prognostic factors related to most severe outcomes related 
to	COVID-19.	In	addition	to	the	above,	BMI	using	Asian	overweight	
cut-off	points	may	limit	generalizability	to	the	wider	population.	The	
current study addressed the biochemical factors affecting outcome 
that might mediate the effect of obesity. We have chosen hyperten-
sion and diabetes as two of the possible mediators showing that gly-
cemia and LDH levels are much stronger predictors. In addition, no 
information	on	IL-1,	IL-6	or	other	inflammatory	markers	was	available	
to	test	the	role	of	BMI	via	other	inflammatory	markers.	Information	
on other comorbidities such as COPD and chronic kidney disease 
was unavailable and therefore not accounted for in the analysis. It 
may be that other comorbidities have a stronger mediating effect on 
COVID-19	severity	but	based	on	data	from	OpenSafely1 this appears 
unlikely.	A	further	limitation	to	our	study	is	that	although	biochemi-
cal/haematological methods may not have necessarily been identical 
at all 14 sites and this may have introduced some error. This would 
tend however to reduce the power to detect significant associations 
and is unlikely to bias our results as there were not any sites with 





tion and should be considered a target for public health measures 
to reduce the impact of the pandemic. The current findings have 
important clinical implications as they suggest that the cardiometa-
bolic	risk	factors	linked	in	a	much	stronger	way	to	COVID-19	severity	
than to other forms of viral pneumonias may be modulating innate 
immune responses in a way that could be mediated by a Warburg 
immunological effect. Our results also suggest the need to look at 







approved the final version.
CONFLIC T OF INTERE S T
The authors who have taken part in this study declared that they do 
not have anything to disclose regarding funding or conflict of inter-
est related to this manuscript.
DATA AVAIL ABILIT Y S TATEMENT
The data that support the findings of this study are available from 
the corresponding author, upon reasonable request.
ORCID
Amrita Vijay  https://orcid.org/0000-0002-9595-5680 





disease 2019 in China. N Engl J Med.	2020;382:1708–1720.
	 3.	 Huang	 C,	 Wang	 Y,	 Li	 X,	 et	 al.	 Clinical	 features	 of	 patients	 in-
fected with 2019 novel coronavirus in Wuhan, China. Lancet. 
2020;395:497–506.
8 of 8  |     YAN ET AL.
	 4.	 Yang	X,	Yu	Y,	Xu	J,	et	al.	Clinical	course	and	outcomes	of	critically	
ill	 patients	with	 SARS-CoV-2	 pneumonia	 in	Wuhan,	 China:	 a	 sin-
gle-centered,	retrospective,	observational	study.	Lancet Respir Med. 
2020;8:475–481.
	 5.	 Petrilli	 CM,	 Jones	 SA,	 Rajagopalan	 H,	 et	 al.	 Factors	 associated	
with	hospitalization	and	critical	 illness	among	4,103	patients	with	
COVID-19	disease	in	New	York	City.	BMJ. 2020;369:m1966.
	 6.	 Simonnet	 A,	 Chetboun	 M,	 Poissy	 J,	 et	 al.	 High	 prevalence	 of	
obesity	 in	 Severe	 Acute	 Respiratory	 Syndrome	 Coronavirus-2	
(SARS-CoV-2)	 requiring	 invasive	 mechanical	 ventilation.	 Obesity. 
2020;28(7):1195–1199.
 7. Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger 
than	60	years	is	a	risk	factor	for	Covid-19	hospital	admission.	Clin. 
Infect. Dis.	2020;71(15):896–897.
	 8.	 Murugan	 AT,	 Sharma	G.	Obesity	 and	 respiratory	 diseases.	Chron 
Respir Dis.	2008;5:233–242.
	 9.	 Stefan	N,	Schick	F,	Häring	H-U.	Causes,	characteristics,	and	conse-
quences of metabolically unhealthy normal weight in humans. Cell 
Metab. 2017;26:292–300.
	10.	 Stefan	 N,	 Birkenfeld	 AL,	 Schulze	 MB,	 Ludwig	 DS.	 Obesity	 and	
impaired	 metabolic	 health	 in	 patients	 with	 COVID-19.	 Nat. Rev. 
Endocrinol.	2020;16(7):341–342.
	11.	 WHO	Expert	Consultation.	Appropriate	body-mass	index	for	Asian	
populations and its implications for policy and intervention strate-
gies. Lancet. 2004;363:157–163.
	12.	 National	Health	Commission	of	the	people’s	Republic	of	China.The	
Guidelines	 for	 the	Diagnosis	 and	 Treatment	 of	New	Coronavirus	
Pneumonia	 (fifth	 edition).	 Available	 from:	 ww.nhc.gov.cn/yzygj/	
s7653	p/20200	2/3b09b	894ac	9b420	4a79d	b5b89	12d44	40.shtml.	
Accessed:	21.08.2020.




ease. Cell Metab. 2017;25:1027–1036.





tematic	 review	and	meta-analysis	of	 intervention	 trials.	Obes Rev. 
2016;17:1067–1079.
	17.	 Lumeng	 CN,	 Saltiel	 AR.	 Inflammatory	 links	 between	 obesity	 and	
metabolic disease. J Clin Invest. 2011;121:2111–2117.
	18.	 Green	WD,	 Beck	MA.	 Obesity	 impairs	 the	 adaptive	 immune	 re-
sponse	to	influenza	virus.	Ann Am Thorac Soc. 2017;14:S406–S409.
	19.	 Klang	E,	Kassim	G,	Soffer	S,	Freeman	R,	Levin	MA,	Reich	DL.	Severe	
obesity	 as	 an	 independent	 risk	 factor	 for	 COVID-19	 mortality	
in	 hospitalized	 patients	 younger	 than	 50.	 Obesity (Silver Spring). 
2020;28:1595–1599.
	20.	 Marik	 PE,	 Bellomo	 R.	 Stress	 hyperglycemia:	 an	 essential	 survival	
response! Crit Care. 2013;17:305.
 21. Zhang Y, Li H, Zhang J, et al. The clinical characteristics and outcomes 
of diabetes mellitus and secondary hyperglycaemia patients with 
coronavirus	disease	2019:	a	single-center,	retrospective,	observa-
tional study in Wuhan. Diabetes Obes Metab. 2020;22:1443–1454.
	22.	 Jafar	N,	Edriss	H,	Nugent	K.	The	effect	of	short-term	hyperglycemia	
on the innate immune system. Am J Med Sci. 2016;351:201–211.
 23. Kornberg MD. The immunologic Warburg effect: Evidence and 





	25.	 Alssema	M,	Boers	HM,	Ceriello	A,	 et	 al.	Diet	 and	 glycaemia:	 the	
markers	 and	 their	 meaning.	 A	 report	 of	 the	 Unilever	 Nutrition	
Workshop. Br J Nutr.	2015;113:239–248.
	26.	 Berry	 S,	Valdes	A,	Davies	R,	 et	 al.	 Predicting	 personal	metabolic	
responses	to	food	using	multi-omics	machine	learning	in	over	1000	
twins and singletons from the UK and US: the PREDICT I Study 
(OR31-01-19).	Curr Dev Nutr.	2019;3:nzz037–OR31.
	27.	 Zeevi	D,	Korem	T,	Zmora	N,	et	al.	Personalized	nutrition	by	predic-
tion of glycemic responses. Cell. 2015;163:1079–1094.
	28.	 Tabák	 AG,	 Herder	 C,	 Rathmann	 W,	 Brunner	 EJ,	 Kivimäki	 M.	







How to cite this article:	Yan	H,	Vijay	A,	Jiang	F,	et	al.	Serum	
glucose, lactate dehydrogenase and hypertension are 
mediators of the effect of body mass index on severity of 
COVID-19.	Endocrinol Diab Metab. 2021;00:e00215. https://
doi.org/10.1002/edm2.215
